Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | ME2 | P23368 | 1/20 | 0.45 |
| ▸ | ME1 | P48163 | 1/20 | 0.45 |
| ▸ | ME3 | Q16798 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7065717 | 1.00 | CA12 (0.48) | CA12CA2CA9AKR1C3ME2 | |
| SCHEMBL7068688 | 0.89 | ALDH1A1 (0.46) | CA12CA2CA9AKR1C3MEN1 | |
| SCHEMBL7068690 | 0.89 | ALDH1A1 (0.46) | CA12CA2CA9AKR1C3MEN1 | |
| SCHEMBL7071263 | 0.89 | POLB (0.51) | MEN1HTTKMT2ACYP3A4 | |
| SCHEMBL7067044 | 0.89 | POLB (0.51) | MEN1HTTKMT2ACYP3A4 | |
| SCHEMBL7069863 | 0.88 | POLB (0.45) | AKR1C3HTT | |
| SCHEMBL7069866 | 0.88 | POLB (0.45) | AKR1C3HTT | |
| SCHEMBL7065445 | 0.87 | ITGB3 (0.40) | AKR1C3 | |
| SCHEMBL7068679 | 0.87 | CHIA (0.48) | AKR1C3ME2ME1ME3MEN1 | |
| SCHEMBL7068676 | 0.87 | CHIA (0.48) | AKR1C3ME2ME1ME3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | THOMPSON LORIN A (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030073701-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073701-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | APP, BACE1, APH1A | CA12 4206/4885CA2 2594/4885CA9 3951/4885 |
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | APP, BACE1, APH1A | CA12 4206/4885CA2 2594/4885CA9 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.